Cancer Killers

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board

Hamilton, ON & Boston, MA – January 13, 2020 – Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB).  CPPIB joins Fusion’s existing group of top-tier investors adding to the US$105 million Series B announced in April 2019.

The financing will primarily be used to expand the use of the Company’s Fast-ClearTM Linker Technology platform by investing in new partnerships and targeting molecules to create novel targeted alpha therapeutics, and to continue to advance its lead asset, FPI-1434, currently in a Phase 1 trial for treating solid tumors.

“Fusion is delighted to welcome the support of CPPIB, and to add another prominent institution to our highly regarded investor base,” said Chief Executive Officer John Valliant.  “CPPIB’s investment reflects strong support for Fusion’s platform technology and people and demonstrates momentum in the radiopharmaceutical industry.  The additional capital provides opportunities for Fusion to accelerate our growth plans and our pipeline of novel and combination therapy assets that can deliver effective and personalized radiation therapies to cancer patients.”

Ends.

About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer.  Using its proprietary Fast-Clear™ Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments.  In preclinical studies, the Company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue.  Fusion’s lead program, FPI-1434, is currently in a Phase 1 trial.  With a proprietary discovery platform, Fusion is actively in-licensing targeting molecules and forming strategic partnerships to expand its pipeline of cancer therapies.  For more information, please visit www.fusionpharma.com

For further information, please contact Vicky La Touche-Price at Seroba on +35316334028.

 

Recent Articles

Fusion Pharmaceuticals Appoints New Chief Medical Officer

23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision […]

Read More
Endotronix 025 Lo (002)

Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial

LISLE, IL – February 18, 2020 – Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to […]

Read More
Cancer Killers

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors

Boston, MA & Hamilton, February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted […]

Read More
The Big Taboo

Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO®

GALWAY, Ireland.  6 February 2020.  Seroba’s portfolio  company, Atlantic Therapeutics, a global medical device manufacturer, today announced that the U.S. […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top